Author + information
Drug coating balloon (DCB) is a new therapeutic option for treatment of obstructive coronary lesions in percutaneous coronary intervention (PCI). There is limited data on the safety and efficacy of DCB in China patients in contemporary clinical registries. We aim to evaluated the clinical efficacy and safety of SeQuent Please paclitaxel-coating balloon in our single center patients in real world clinical practice.
Between August 2014 to March 2015, 80 patients (51% male, mean age 66 ± 10 years) with a total of 85 coronary lesions were treated with SeQuent Please DCB. The primary endpoint was major adverse cardiac events (MACE) composite of cardiovascular death, target vessel related myocardial infarction (MI) and target lesion revascularization (TLR) at 9 months follow-up.
The majority of patients presented with acute coronary syndrome (76%). An average DCB diameter was 2.7±0.45 mm and average total length was 15.8±3.9 mm. At 9 months' follow-up, 3.75% of patients developed MACE. MACE was mainly driven by TLR(1.25%) followed by target vessel related myocardial infarction (1.25%) and cardiovascular death (2.5%).
SeQuent Please DCB was a safe and effective treatment modality in our single center Chinese patients with a low incidence of MACE observed at 9 months follow-up.